Status:
UNKNOWN
Lean Body Mass and Side Effects in Patients With Lymphoma
Lead Sponsor:
Jens Rikardt Andersen
Conditions:
Malignant Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in p...
Eligibility Criteria
Inclusion
- Patients receiving myelosuppressive treatment for malignant lymphoma assessed by the investigator.
- Legal of age
Exclusion
- ECOG Performance Status ≥2
- People who cannot speak and understand Danish
- Pregnant and breastfeeding
- Dementia
Key Trial Info
Start Date :
February 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 3 2021
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT04698616
Start Date
February 9 2020
End Date
March 3 2021
Last Update
January 7 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Copenhagen
Copenhagen, Frederiksberg, Denmark, 1958
2
Sjællands Universitetshospital, Hæmatologisk Afdeling H60
Roskilde, Denmark, 4000